222 related articles for article (PubMed ID: 15484403)
1. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck.
Akervall J; Kurnit DM; Adams M; Zhu S; Fisher SG; Bradford CR; Carey TE
Acta Otolaryngol; 2004 Sep; 124(7):851-7. PubMed ID: 15484403
[TBL] [Abstract][Full Text] [Related]
2. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
3. Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma.
Nakashima T; Clayman GL
Arch Otolaryngol Head Neck Surg; 2000 Aug; 126(8):957-61. PubMed ID: 10922227
[TBL] [Abstract][Full Text] [Related]
4. The effect of cyclin D1 overexpression in human head and neck cancer cells.
Nakashima T; Kuratomi Y; Yasumatsu R; Masuda M; Koike K; Umezaki T; Clayman GL; Nakagawa T; Komune S
Eur Arch Otorhinolaryngol; 2005 May; 262(5):379-83. PubMed ID: 15368064
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck.
Michalides RJ; van Veelen NM; Kristel PM; Hart AA; Loftus BM; Hilgers FJ; Balm AJ
Arch Otolaryngol Head Neck Surg; 1997 May; 123(5):497-502. PubMed ID: 9158396
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma.
Kothari V; Mulherkar R
Anticancer Res; 2012 Jan; 32(1):121-8. PubMed ID: 22213296
[TBL] [Abstract][Full Text] [Related]
7. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.
Akervall J; Brun E; Dictor M; Wennerberg J
Acta Oncol; 2001; 40(4):505-11. PubMed ID: 11504311
[TBL] [Abstract][Full Text] [Related]
9. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Wang MB; Yip HT; Srivatsan ES
Laryngoscope; 2001 Jun; 111(6):982-8. PubMed ID: 11404608
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck.
Henriksson E; Kjellén E; Baldetorp B; Bendahl PO; Borg A; Brun E; Mertens F; Ohlsson T; Rennstam K; Wennerberg J; Wahlberg P
J Exp Clin Cancer Res; 2009 Feb; 28(1):17. PubMed ID: 19216775
[TBL] [Abstract][Full Text] [Related]
11. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
12. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.
Xi S; Dyer KF; Kimak M; Zhang Q; Gooding WE; Chaillet JR; Chai RL; Ferrell RE; Zamboni B; Hunt J; Grandis JR
J Natl Cancer Inst; 2006 Feb; 98(3):181-9. PubMed ID: 16449678
[TBL] [Abstract][Full Text] [Related]
13. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma.
Yamano Y; Uzawa K; Saito K; Nakashima D; Kasamatsu A; Koike H; Kouzu Y; Shinozuka K; Nakatani K; Negoro K; Fujita S; Tanzawa H
Int J Cancer; 2010 Jan; 126(2):437-49. PubMed ID: 19569180
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
Biliran H; Wang Y; Banerjee S; Xu H; Heng H; Thakur A; Bollig A; Sarkar FH; Liao JD
Clin Cancer Res; 2005 Aug; 11(16):6075-86. PubMed ID: 16115953
[TBL] [Abstract][Full Text] [Related]
15. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.
Li F; Shanmugam MK; Siveen KS; Wang F; Ong TH; Loo SY; Swamy MM; Mandal S; Kumar AP; Goh BC; Kundu T; Ahn KS; Wang LZ; Hui KM; Sethi G
Oncotarget; 2015 Mar; 6(7):5147-63. PubMed ID: 25762616
[TBL] [Abstract][Full Text] [Related]
16. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression.
Akervall JA; Michalides RJ; Mineta H; Balm A; Borg A; Dictor MR; Jin Y; Loftus B; Mertens F; Wennerberg JP
Cancer; 1997 Jan; 79(2):380-9. PubMed ID: 9010112
[TBL] [Abstract][Full Text] [Related]
17. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.
Masuda M; Suzui M; Yasumatu R; Nakashima T; Kuratomi Y; Azuma K; Tomita K; Komiyama S; Weinstein IB
Cancer Res; 2002 Jun; 62(12):3351-5. PubMed ID: 12067972
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
